UK markets close in 3 hours 43 minutes
  • FTSE 100

    5,621.17
    -107.82 (-1.88%)
     
  • FTSE 250

    17,303.68
    -284.03 (-1.61%)
     
  • AIM

    957.81
    -14.72 (-1.51%)
     
  • GBP/EUR

    1.1026
    -0.0035 (-0.31%)
     
  • GBP/USD

    1.2924
    -0.0117 (-0.90%)
     
  • BTC-GBP

    10,215.75
    -305.21 (-2.90%)
     
  • CMC Crypto 200

    261.44
    +0.15 (+0.06%)
     
  • S&P 500

    3,390.68
    -10.29 (-0.30%)
     
  • DOW

    27,463.19
    -222.19 (-0.80%)
     
  • CRUDE OIL

    37.76
    -1.81 (-4.57%)
     
  • GOLD FUTURES

    1,880.80
    -31.10 (-1.63%)
     
  • NIKKEI 225

    23,418.51
    -67.29 (-0.29%)
     
  • HANG SENG

    24,708.80
    -78.39 (-0.32%)
     
  • DAX

    11,639.18
    -424.39 (-3.52%)
     
  • CAC 40

    4,579.98
    -150.68 (-3.19%)
     

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S
·3-min read

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 28 September 2020 – On 6 August 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.

Under the programme initiated 6 August 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 6 August 2020 to 28 October 2020.

Since the announcement as of 21 September 2020, the following transactions have been made:

Number of
B shares

Average
purchase price

Transaction
value, DKK

Accumulated, last announcement

3,534,491

1,476,258,404

21 September 2020

110,000

436.04

47,964,267

22 September 2020

110,000

436.37

48,000,958

23 September 2020

110,000

440.47

48,451,214

24 September 2020

110,000

439.22

48,314,084

25 September 2020

110,000

435.35

47,888,409

Accumulated under the programme

4,084,491

1,716,877,335

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 24,132,394 B shares of DKK 0.20 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 25 September 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 24,143,670 B shares at an average share price of DKK 425.27 per B share equal to a transaction value of DKK 10,267,665,067.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:

Anne Margrethe Hauge

+45 4442 3450

amhg@novonordisk.com

Ken Inchausti (US)

+1 609 240 9429

kiau@novonordisk.com

Investors:

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

Valdemar Borum Svarrer

+45 3079 0301

jvls@novonordisk.com

Ann Søndermølle Rendbæk

+45 3075 2253

arnd@novonordisk.com

Mark Joseph Root

+45 3079 4211

mjhr@novonordisk.com

Kristoffer Due Berg (US)

+1 609 235 2989

krdb@novonordisk.com


Company announcement no. 56 / 2020

Attachment